Michael Z Su1, Fatima Memon2, Howard M Lau3, Andrew J Brooks3, Manish I Patel3, Henry H Woo4, Simon V Bariol3, Philip Vladica2. 1. Department of Surgery, University of Sydney, Westmead Hospital, Corner of Hawkesbury and Darcy Roads, Westmead, NSW, 2145, Australia. michael.zy.su@sydney.edu.au. 2. Department of Radiology, Westmead Hospital, Sydney, NSW, Australia. 3. Department of Urology, Westmead Hospital, Sydney, NSW, Australia. 4. Sydney Medical School, University of Sydney, Wahroonga, NSW, Australia.
Abstract
PURPOSE: To evaluate the safety and efficacy of percutaneous radiofrequency ablation (RFA) for localised renal cell carcinoma (RCC) and examine potential associations between age, gender, tumour size, location, chronic kidney disease, comorbidities, learning curve and local recurrence. METHODS: We retrospectively analysed survival outcomes for patients with biopsy-proven RCC treated by RFA at Westmead Hospital. Complication data were gathered from all patients that underwent renal RFA. 3 and 5 year local recurrence-free (RFS), disease-free (DFS) and overall survival (OS) outcomes were reported. Univariate and multivariate analysis was used to examine each potential predictor. RESULTS: A total of 168 patients were eligible for the study. Forty-eight patients with biopsy-proven RCC had minimum 3-year follow-up. Our complication rate was 1.2 % (2/168) and local recurrence rate 10.4 % (5/48). Five-year RFS, DFS and OS were 86.8, 82.3 and 92.6 % on a median 4.1-year follow-up (IQR 3.4-4.9). None of the patient or tumour-specific characteristics were associated with RFS. CONCLUSION: Radiofrequency ablation performed at our centre was a safe and effective procedure with low complication rates and durable RFS. Tumour characteristics, comorbidities and learning curve were not associated with local recurrence.
PURPOSE: To evaluate the safety and efficacy of percutaneous radiofrequency ablation (RFA) for localised renal cell carcinoma (RCC) and examine potential associations between age, gender, tumour size, location, chronic kidney disease, comorbidities, learning curve and local recurrence. METHODS: We retrospectively analysed survival outcomes for patients with biopsy-proven RCC treated by RFA at Westmead Hospital. Complication data were gathered from all patients that underwent renal RFA. 3 and 5 year local recurrence-free (RFS), disease-free (DFS) and overall survival (OS) outcomes were reported. Univariate and multivariate analysis was used to examine each potential predictor. RESULTS: A total of 168 patients were eligible for the study. Forty-eight patients with biopsy-proven RCC had minimum 3-year follow-up. Our complication rate was 1.2 % (2/168) and local recurrence rate 10.4 % (5/48). Five-year RFS, DFS and OS were 86.8, 82.3 and 92.6 % on a median 4.1-year follow-up (IQR 3.4-4.9). None of the patient or tumour-specific characteristics were associated with RFS. CONCLUSION: Radiofrequency ablation performed at our centre was a safe and effective procedure with low complication rates and durable RFS. Tumour characteristics, comorbidities and learning curve were not associated with local recurrence.
Authors: Ronald J Zagoria; Joseph A Pettus; Morgan Rogers; David M Werle; David Childs; John R Leyendecker Journal: Urology Date: 2011-04-13 Impact factor: 2.649
Authors: Eric Wehrenberg-Klee; Timothy W I Clark; Stanley B Malkowicz; Michael C Soulen; Alan J Wein; Jeffrey I Mondschein; Keith Van Arsdalen; Thomas J Guzzo; S William Stavropoulos Journal: J Vasc Interv Radiol Date: 2011-10-22 Impact factor: 3.464
Authors: Sara L Best; Samuel K Park; Ramy F Youssef; Ramy F Yaacoub; Ephrem O Olweny; Yung K Tan; Clayton Trimmer; Jeffrey A Cadeddu Journal: J Urol Date: 2012-02-14 Impact factor: 7.450
Authors: Debra A Gervais; Ronald S Arellano; Francis J McGovern; W Scott McDougal; Peter R Mueller Journal: AJR Am J Roentgenol Date: 2005-07 Impact factor: 3.959
Authors: D Brooke Johnson; Stephen B Solomon; Li-Ming Su; Edward D Matsumoto; Louis R Kavoussi; Stephen Y Nakada; Timothy D Moon; W Bruce Shingleton; Jeffrey A Cadeddu Journal: J Urol Date: 2004-09 Impact factor: 7.450
Authors: Joshua M Stern; Robert Svatek; Sangtae Park; Michael Hermann; Yair Lotan; Arthur I Sagalowsky; Jeffrey A Cadeddu Journal: BJU Int Date: 2007-08 Impact factor: 5.588
Authors: Jay D Raman; Ganesh V Raj; Steven M Lucas; Steve K Williams; Eric M Lauer; Kamran Ahrar; Surena F Matin; Raymond J Leveillee; Jeffrey A Cadeddu Journal: BJU Int Date: 2009-08-13 Impact factor: 5.588
Authors: R Damm; T Streitparth; P Hass; M Seidensticker; C Heinze; M Powerski; J J Wendler; U B Liehr; K Mohnike; M Pech; J Ricke Journal: Strahlenther Onkol Date: 2019-07-25 Impact factor: 3.621